NSD2 and plasma cell myeloma: Future studies are warranted to further explore the effect of FGFR3 inhibition in multiple myeloma with t(4;14) and a better understanding of the implications of FGFR3 oncogenic partners and other partners like MMSET that play a preeminent oncogenic role in patients with t(4;14) [34,35].